scispace - formally typeset
J

Josemir W. Sander

Researcher at UCL Institute of Neurology

Publications -  705
Citations -  44517

Josemir W. Sander is an academic researcher from UCL Institute of Neurology. The author has contributed to research in topics: Epilepsy & Population. The author has an hindex of 106, co-authored 680 publications receiving 39038 citations. Previous affiliations of Josemir W. Sander include University of Cincinnati & National Institute for Health Research.

Papers
More filters
Journal ArticleDOI

Antiepileptic drugs and suicide risk: could stopping medications pose a greater hazard?

TL;DR: A total of 11 compounds were involved in 199 placebo-controlled trials, with over 27,000 individuals taking AEDs and 16,000 on placebo, and the overall odds ratio for spontaneously reported suicidal behavior or ideation in those taking active drugs was 1.8.
Journal Article

Levetiracetam: a new therapeutic option for refractory epilepsy.

TL;DR: Preliminary data suggest that LEV has efficacy in primary generalised epilepsy and further randomised trials are under way, and the combination of potent antiepileptic properties with a relatively mild adverse effect profile makes LEV an attractive adjunctive therapy for partial seizures.
Journal ArticleDOI

Cannabidiol in patients with treatment-resistant epilepsy

TL;DR: This study shows that, contrary to what many hope, cannabidiol is probably not the magic bullet for severe childhood epilepsy, and properly randomised controlled trials are urgently needed to assess the safety profi le and effi cacy of cannabdiol are similar to those of other antiepileptic drugs, or worse.
Journal Article

Epilepsy and recreational scuba diving an absolute contraindication or can there be exceptions

TL;DR: It is suggested that people with epilepsy who wish to engage in diving, and the physicians who certify fitness to dive, should be provided with all the available evidence.
Journal ArticleDOI

Sodium valproate for epilepsy in rural China: An efficacy and safety assessment in primary care

TL;DR: VPA had favourable efficacy, few side effects and overall good acceptability, and was also relatively cheap, a suitable alternative to phenobarbital as treatment of convulsive epilepsy in rural areas of China.